- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Janssen Announces Worldwide Agreement To Develop And Commercialize JAK Inhibitor For Immunological Diseases
Orally Administered Investigational Therapy Expands Global Immunology Portfolio
First Results from Phase 3 CANVAS Trial Show Canagliflozin as Add-on Therapy to Insulin Lowered Blood Sugar Levels in Patients with Type 2 Diabetes at an Elevated Risk for Cardiovascular Disease
Canagliflozin also shown effective and generally well-tolerated in patients with type 2 diabetes aged 55 to 80 in separate Phase 3 study
New ZYTIGA® (abiraterone acetate) Data on Pain and Function Presented at the ESMO 2012 Congress (European Society for Medical Oncology)
New Analyses from Phase 3 COU-AA-302 Study Also Suggest Radiographic Progression-Free Survival Positively Associated with Overall Survival
Subcutaneous VELCADE® Approved In the EU for the Treatment of Multiple Myeloma
Simpler, easier route of administration offers improved safety and convenience, with maintained efficacy
DACOGEN® Approved In the European Union for the Treatment of Acute Myeloid Leukaemia
New treatment offers clinically significant benefit for patients
Janssen Connected Health Challenge Europe 2012 Launching To Spur Healthcare Innovation
Janssen Connected Health Challenge seeks transformational care ideas and offers awards totalling €30,000 to develop winning solutions
FDA Approves Expansion of Dosing Window to Help Avoid Missed Doses in INVEGA® SUSTENNA® Updated Product Label
Additional Prescribing Information Revisions Also Reflected in Updated Product Label
Johnson & Johnson Symposium Honors 2012 Recipients of the Dr. Paul Janssen Award for Biomedical Research
Dr. Victor Ambros and Dr. Gary Ruvkun Honored for Discovery of microRNAs;Symposium Celebrates the Power of Science to Change the World